Rituxan Shows Sustained Benefit For RA In Phase II Trials

Results from Phase II clinical trials for Rituxan were announced by Genentech, IDEC Pharmaceuticals, and Roche, at the 2003 American College of Rheumatology meeting in Orlando, Florida. The news is encouraging. Read the details.

UPDATE: On 03/01/2006, Rituxan (rituximab) was FDA approved to be used in combination with methotrexate to treat rheumatoid arthritis by reducing the signs and symptoms in adult patients who have moderately-to-severely active rheumatoid arthritis and have failed one or more anti-TNF drugs e.g. Enbrel (etanercept), Remicade (infliximab), or Humira (adalimumab).

• Rituxan Approved for Rheumatoid Arthritis - The Facts of Rituxan
• Subsequent Rituxan Treatment Yields Better Outcomes
• More About Rituxan (rituximab)